-
New
Net Present Value Model: Acelyrin Inc’s Izokibep
Empower your strategies with our Net Present Value Model: Acelyrin Inc's Izokibep report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Acelyrin Inc’s Lonigutamab Ugodotin
Empower your strategies with our Net Present Value Model: Acelyrin Inc's Lonigutamab Ugodotin report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VB-119 in Focal Segmental Glomerulosclerosis (FSGS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VB-119 in Focal Segmental Glomerulosclerosis (FSGS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VB-119 in Focal Segmental Glomerulosclerosis (FSGS) Drug Details: VB-119 is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – VB-119 in Kidney Disease (Nephropathy)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VB-119 in Kidney Disease (Nephropathy) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VB-119 in Kidney Disease (Nephropathy) Drug Details: VB-119 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ociperlimab in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ociperlimab in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ociperlimab in Adenocarcinoma Of The Gastroesophageal Junction Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tomivosertib Hydrochloride in Head And Neck Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tomivosertib Hydrochloride in Head And Neck Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tomivosertib Hydrochloride in Head And Neck Cancer Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Moxidectin in Strongyloidiasis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Moxidectin in Strongyloidiasis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Moxidectin in Strongyloidiasis Drug Details: Moxidectin is a semisynthetic derivative of nemadectin...
-
Product Insights
Intermediate Uveitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Intermediate Uveitis - Drugs In Development, 2023’, provides an overview of the Intermediate Uveitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Intermediate Uveitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Panuveitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Panuveitis - Drugs In Development, 2023’, provides an overview of the Panuveitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Panuveitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Non-infectious Uveitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Non-infectious Uveitis - Drugs In Development, 2023’, provides an overview of the Non-infectious Uveitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Non-infectious Uveitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...